lvrachЛечащий ВрачLechaschi Vrach1560-51752687-1181ООО «Издательство "Открытые системы"»10.26295/OS.2020.75.99.012lvrach-141Research ArticleСтатьиУрсодезоксихолевая кислота и болезни печениUrsodeoxycholic acid and hepatic diseasesВолынецГ. В.VolynetsG. V.volynec_g@mail.ruХавкинА. И.KhavkinA. I.noemail@neicon.ruФГБОУ ВО РНИМУ им. Н. И. Пирогова МЗ РФRussian Federation202023062021066268Copyright © Волынец Г.В., Хавкин А.И., 20212021Волынец Г.В., Хавкин А.И.Volynets G.V., Khavkin A.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.lvrach.ru/jour/article/view/141

Урсодезоксихолевая кислота (УДХК) - гидрофильная желчная кислота, которая является мощным антиоксидантом и в настоящее время используется в качестве панацеи для медикаментозного лечения широкого спектра заболеваний печени.Показана фармакокинетика УДХК, механизмы действия, среди которых выделены защита холангиоцитов от цитотоксичности гидрофобных желчных кислот; стимуляция гепатобилиарной секреции; защита гепатоцитов от апоптоза, вызванного желчными кислотами, а также использование УДХК при различных холестатических заболеваниях: первичный билиарный цирроз, склерозирующий холангит, прогрессирующие и непрогрессирующие формы семейного внутрипеченочного холестаза, муковисцидоз, внутрипеченочный холестаз беременных, лекарственно индуцированный холестаз, гипофосфолипид-ассоциированная желчнокаменная болезнь.УДХК широко используется в терапии различных заболеваний печени, а при холестатических заболеваниях она является препаратом терапии первой линии. Несмотря на то, что во многих случаях лечение УДХК не является патогенетическим, ее применение сопровождается уменьшением кожного зуда, улучшением биохимических показателей и улучшает результаты гистологических и холангиографических исследований. Поэтому проводимое лечение является благоприятным и направлено больше на купирование осложнений при холестатических заболеваниях. Все пациенты, получавшие УДХК при первичным склерозирующем холангите, имели более благоприятное течение заболевания с более редким появлением серьезных осложнений.

Ursodeoxycholic acid (UDCA) is a hydrophilic bile acid, a potent antioxidant, which is currently used as a «panacea» for drug treatment of wide range of hepatic diseases. Pharmacokinetics and action mechanisms of UDCA were shown, as well as UDCA use in different cholestatic diseases. UDCA is widely used in the therapy of different hepatic diseases, and in cholestatic diseases, it is the firstline therapeutic drug. 

ГепатологияЗащита гепатоцитовТерапияУрсодезоксихолевая кислотаХолестатические болезниursodeoxycholic acidhepatocyte protectioncholestatic diseasesReferencesChen Y. S., Liu H. M., Lee T. Y. Ursodeoxycholic Acid Regulates Hepatic Energy Homeostasis and White Adipose Tissue Macrophages Polarization in Leptin-Deficiency Obese Mice // Cells. 2019, Mar 16; 8 (3): pii: E253. DOI: 10.3390/cells8030253.Chen Y. S., Liu H. M., Lee T. Y. Ursodeoxycholic Acid Regulates Hepatic Energy Homeostasis and White Adipose Tissue Macrophages Polarization in Leptin-Deficiency Obese Mice // Cells. 2019, Mar 16; 8 (3): pii: E253. DOI: 10.3390/cells8030253.Bell S. M., Barnes K., Clemmens H., Al-Rafiah A. R., Al-Ofi E. A., Leech V., Bandmann O., Shaw P. J., Blackburn D. J., Ferraiuolo L., Mortiboys H. Ursodeoxycholic Acid Improves Mitochondrial Function and Redistributes Drp1 in Fibroblasts from Patients with Either Sporadic or Familial Alzheimer's Disease // J Mol Biol. 2018; 430 (21): 3942-3953. DOI: 10.1016/j.jmb.2018.08.019.Bell S. M., Barnes K., Clemmens H., Al-Rafiah A. R., Al-Ofi E. A., Leech V., Bandmann O., Shaw P. J., Blackburn D. J., Ferraiuolo L., Mortiboys H. Ursodeoxycholic Acid Improves Mitochondrial Function and Redistributes Drp1 in Fibroblasts from Patients with Either Sporadic or Familial Alzheimer's Disease // J Mol Biol. 2018; 430 (21): 3942-3953. DOI: 10.1016/j.jmb.2018.08.019.Abdelkader N. F., Safar M. M., Salem H. A. Ursodeoxycholic Acid Ameliorates Apoptotic Cascade in the Rotenone Model of Parkinson's Disease: Modulation of Mitochondrial Perturbations // Mol Neurobiol. 2016; 53 (2): 810-817. DOI: 10.1007/s12035-014-9043-8.Abdelkader N. F., Safar M. M., Salem H. A. Ursodeoxycholic Acid Ameliorates Apoptotic Cascade in the Rotenone Model of Parkinson's Disease: Modulation of Mitochondrial Perturbations // Mol Neurobiol. 2016; 53 (2): 810-817. DOI: 10.1007/s12035-014-9043-8.Manley S., Ding W. Role of farnesoid X receptor and bile acids in alcoholic liver disease // Acta Pharm Sin B. 2015; 5 (2): 158-167. DOI: 10.1016/j.apsb.2014.12.011.Manley S., Ding W. Role of farnesoid X receptor and bile acids in alcoholic liver disease // Acta Pharm Sin B. 2015; 5 (2): 158-167. DOI: 10.1016/j.apsb.2014.12.011.Bellentani S. Immunomodulating and anti-apoptotic action of ursodeoxycholic acid: where are we and where should we go? // Eur J Gastroenterol Hepatol. 2005, Feb; 17 (2): 137-140. DOI: 10.1097/00042737-200502000-00001.Bellentani S. Immunomodulating and anti-apoptotic action of ursodeoxycholic acid: where are we and where should we go? // Eur J Gastroenterol Hepatol. 2005, Feb; 17 (2): 137-140. DOI: 10.1097/00042737-200502000-00001.S?nchez-Garc?a A., Sahebkar A., Simental-Mend?a M., Simental-Mend?a L. E. Effect of ursodeoxycholic acid on glycemic markers: A systematic review and meta-analysis of clinical trials // Pharmacol Res. 2018; 135: 144-149. DOI: 10.1016/j.phrs.2018.08.008.S?nchez-Garc?a A., Sahebkar A., Simental-Mend?a M., Simental-Mend?a L. E. Effect of ursodeoxycholic acid on glycemic markers: A systematic review and meta-analysis of clinical trials // Pharmacol Res. 2018; 135: 144-149. DOI: 10.1016/j.phrs.2018.08.008.Ma H., Sales V. M., Wolf A. R., Subramanian S., Matthews T. J., Chen M., Sharma A., Gall W., Kulik W., Cohen D. E., Adachi Y., Griffin N. W., Gordon J. I., Patti M. E., Isganaitis E. Attenuated Effects of Bile Acids on Glucose Metabolism and Insulin Sensitivity in a Male Mouse Model of Prenatal Undernutrition // Endocrinology. 2017; 158 (8): 2441-2452. DOI: 10.1210/en.2017-00288.Ma H., Sales V. M., Wolf A. R., Subramanian S., Matthews T. J., Chen M., Sharma A., Gall W., Kulik W., Cohen D. E., Adachi Y., Griffin N. W., Gordon J. I., Patti M. E., Isganaitis E. Attenuated Effects of Bile Acids on Glucose Metabolism and Insulin Sensitivity in a Male Mouse Model of Prenatal Undernutrition // Endocrinology. 2017; 158 (8): 2441-2452. DOI: 10.1210/en.2017-00288.Zhang Y., Jiang R., Zheng X., Lei S., Huang F., Xie G., Kwee S., Yu H., Farrar C., Sun B., Zhao A., Jia W. Ursodeoxycholic acid accelerates bile acid enterohepatic circulation // Br J Pharmacol. 2019; 176 (16): 2848-2863. DOI: 10.1111/bph.14705.Zhang Y., Jiang R., Zheng X., Lei S., Huang F., Xie G., Kwee S., Yu H., Farrar C., Sun B., Zhao A., Jia W. Ursodeoxycholic acid accelerates bile acid enterohepatic circulation // Br J Pharmacol. 2019; 176 (16): 2848-2863. DOI: 10.1111/bph.14705.Ducker G. S., Chen L., Morscher R. J., Ghergurovich J. M., Esposito M., Teng X., Kang Y., Rabinowitz J. D. Reversal of Cytosolic One-Carbon Flux Compensates for Loss of the Mitochondrial Folate Pathway // Cell Metab. 2016; 24 (4): 640-641. DOI: 10.1016/j.cmet.2016.09.011.Ducker G. S., Chen L., Morscher R. J., Ghergurovich J. M., Esposito M., Teng X., Kang Y., Rabinowitz J. D. Reversal of Cytosolic One-Carbon Flux Compensates for Loss of the Mitochondrial Folate Pathway // Cell Metab. 2016; 24 (4): 640-641. DOI: 10.1016/j.cmet.2016.09.011.Ozcan U., Yilmaz E., Ozcan L., Furuhashi M., Vaillancourt E., Smith R. O., G?rg?n C. Z., Hotamisligil G. S. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes // Science. 2006; 313 (5790): 1137-1140. DOI: 10.1126/science.1128294.Ozcan U., Yilmaz E., Ozcan L., Furuhashi M., Vaillancourt E., Smith R. O., G?rg?n C. Z., Hotamisligil G. S. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes // Science. 2006; 313 (5790): 1137-1140. DOI: 10.1126/science.1128294.Dos Santos N. A., Carvalho Rodrigues M. A., Martins N. M., dos Santos A. C. Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update // Arch Toxicol. 2012; 86 (8): 1233-1250. DOI: 10.1007/s00204-012-0821-7.Dos Santos N. A., Carvalho Rodrigues M. A., Martins N. M., dos Santos A. C. Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update // Arch Toxicol. 2012; 86 (8): 1233-1250. DOI: 10.1007/s00204-012-0821-7.Goossens J. F., Bailly C. Ursodeoxycholic acid and cancer: From chemoprevention to chemotherapy // Pharmacol Ther. 2019; 203: 107396. DOI: 10.1016/j.pharmthera.2019.107396.Goossens J. F., Bailly C. Ursodeoxycholic acid and cancer: From chemoprevention to chemotherapy // Pharmacol Ther. 2019; 203: 107396. DOI: 10.1016/j.pharmthera.2019.107396.Lee S., Cho Y. Y., Cho E. J., Yu S. J., Lee J. H., Yoon J. H., Kim Y. J. Synergistic effect of ursodeoxycholic acid on the antitumor activity of sorafenib in hepatocellular carcinoma cells via modulation of STAT3 and ERK // Int J Mol Med. 2018; 42 (5): 2551-2559. DOI: 10.3892/ijmm.2018.3807.Lee S., Cho Y. Y., Cho E. J., Yu S. J., Lee J. H., Yoon J. H., Kim Y. J. Synergistic effect of ursodeoxycholic acid on the antitumor activity of sorafenib in hepatocellular carcinoma cells via modulation of STAT3 and ERK // Int J Mol Med. 2018; 42 (5): 2551-2559. DOI: 10.3892/ijmm.2018.3807.Van Heumen B. W., Roelofs H. M., Te Morsche R. H., Marian B., Nagengast F. M., Peters W. H. Celecoxib and tauro-ursodeoxycholic acid co-treatment inhibits cell growth in familial adenomatous polyposis derived LT97 colon adenoma cells // Exp Cell Res. 2012; 318 (7): 819-827. DOI: 10.1016/j.yexcr.2012.02.004.Van Heumen B. W., Roelofs H. M., Te Morsche R. H., Marian B., Nagengast F. M., Peters W. H. Celecoxib and tauro-ursodeoxycholic acid co-treatment inhibits cell growth in familial adenomatous polyposis derived LT97 colon adenoma cells // Exp Cell Res. 2012; 318 (7): 819-827. DOI: 10.1016/j.yexcr.2012.02.004.Goet J. C., Hirschfield G. M. Guideline review: British Society of Gastroenterology/UK-PBC Primary Biliary Cholangitis treatment and management guidelines // Frontline Gastroenterol. 2019; 10 (3): 316-319. DOI: 10.1136/flgastro-2018-101109.Goet J. C., Hirschfield G. M. Guideline review: British Society of Gastroenterology/UK-PBC Primary Biliary Cholangitis treatment and management guidelines // Frontline Gastroenterol. 2019; 10 (3): 316-319. DOI: 10.1136/flgastro-2018-101109.Hirschfield G. M., Dyson J. K., Alexander G. J. M., Chapman M. H., Collier J., H?bscher S., Patanwala I., Pereira S. P., Thain C., Thorburn D., Tiniakos D., Walmsley M., Webster G., Jones D. E. J. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines // Gut. 2018; 67 (9): 1568-1594. DOI: 10.1136/gutjnl-2017-315259.Hirschfield G. M., Dyson J. K., Alexander G. J. M., Chapman M. H., Collier J., H?bscher S., Patanwala I., Pereira S. P., Thain C., Thorburn D., Tiniakos D., Walmsley M., Webster G., Jones D. E. J. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines // Gut. 2018; 67 (9): 1568-1594. DOI: 10.1136/gutjnl-2017-315259.Hofmann A. F. Pharmacology of ursodeoxycholic acid, an enterohepatic drug // Scand J Gastroenterol Suppl. 1994; 204: 1-15. DOI: 10.3109/00365529409103618.Hofmann A. F. Pharmacology of ursodeoxycholic acid, an enterohepatic drug // Scand J Gastroenterol Suppl. 1994; 204: 1-15. DOI: 10.3109/00365529409103618.G?ld?tuna S., Zimmer G., Imhof M., Bhatti S., You T., Leuschner U. Molecular aspects of membrane stabilization by ursodeoxycholate // Gastroenterology. 1993; 104 (6): 1736-1744. DOI: 10.1016/0016-5085 (93)90653-t.G?ld?tuna S., Zimmer G., Imhof M., Bhatti S., You T., Leuschner U. Molecular aspects of membrane stabilization by ursodeoxycholate // Gastroenterology. 1993; 104 (6): 1736-1744. DOI: 10.1016/0016-5085 (93)90653-t.Heuman D. M., Bajaj R. S., Lin Q. Adsorption of mixtures of bile salt taurine conjugates to lecithin-cholesterol membranes: implications for bile salt toxicity and cytoprotection // J Lipid Res. 1996; 37: 562-573. PMID: 8728319.Heuman D. M., Bajaj R. S., Lin Q. Adsorption of mixtures of bile salt taurine conjugates to lecithin-cholesterol membranes: implications for bile salt toxicity and cytoprotection // J Lipid Res. 1996; 37: 562-573. PMID: 8728319.Van Nieuwkerk C. M., Elferink R. P., Groen A. K., Ottenhoff R., Tytgat G. N., Dingemans K. P., van den Bergh Weerman M. A., Offerhaus G. J. Effects of Ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene // Gastroenterology. 1996; 111 (1): 165-171. DOI: 10.1053/gast.1996.v111.pm8698195.Van Nieuwkerk C. M., Elferink R. P., Groen A. K., Ottenhoff R., Tytgat G. N., Dingemans K. P., van den Bergh Weerman M. A., Offerhaus G. J. Effects of Ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene // Gastroenterology. 1996; 111 (1): 165-171. DOI: 10.1053/gast.1996.v111.pm8698195.Beuers U., Bilzer M., Chittattu A., Kullak-Ublick G. A., Keppler D., Paumgartner G., Dombrowski F. Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver // Hepatology. 2001; 33 (5): 1206-1216. DOI: 10.1053/jhep.2001.24034.Beuers U., Bilzer M., Chittattu A., Kullak-Ublick G. A., Keppler D., Paumgartner G., Dombrowski F. Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver // Hepatology. 2001; 33 (5): 1206-1216. DOI: 10.1053/jhep.2001.24034.Heathcote E. J., Cauch-Dudek K., Walker V., Bailey R. J., Blendis L. M., Ghent C. N., Michieletti P., Minuk G. Y., Pappas S. C., Scully L. J., et al. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis // Hepatology. 1994; 19 (5): 1149-1156. PMID: 8175136.Heathcote E. J., Cauch-Dudek K., Walker V., Bailey R. J., Blendis L. M., Ghent C. N., Michieletti P., Minuk G. Y., Pappas S. C., Scully L. J., et al. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis // Hepatology. 1994; 19 (5): 1149-1156. PMID: 8175136.Par?s A., Caballer?a L., Rod?s J., Bruguera M., Rodrigo L., Garc?a-Plaza A., Berenguer J., Rodr?guez-Mart?nez D., Mercader J., Velicia R. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver // J Hepatol. 2000; 32 (4): 561-566. DOI: 10.1016/s0168-8278 (00)80216-0.Par?s A., Caballer?a L., Rod?s J., Bruguera M., Rodrigo L., Garc?a-Plaza A., Berenguer J., Rodr?guez-Mart?nez D., Mercader J., Velicia R. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver // J Hepatol. 2000; 32 (4): 561-566. DOI: 10.1016/s0168-8278 (00)80216-0.Poupon R. E., Balkau B., Eschwege E., Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group // N Engl J Med. 1991; 324 (22): 1548-1554. DOI: 10.1056/NEJM199105303242204.Poupon R. E., Balkau B., Eschwege E., Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group // N Engl J Med. 1991; 324 (22): 1548-1554. DOI: 10.1056/NEJM199105303242204.Stiehl A., Walker S., Stiehl L., Rudolph G., Hofmann W. J., Theilmann L. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period // J Hepatol. 1994; 20 (1): 57-64. DOI: 10.1016/s0168-8278 (05)80467-2.Stiehl A., Walker S., Stiehl L., Rudolph G., Hofmann W. J., Theilmann L. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period // J Hepatol. 1994; 20 (1): 57-64. DOI: 10.1016/s0168-8278 (05)80467-2.Alpini G., Baiocchi L., Glaser S., Ueno Y., Marzioni M., Francis H., Phinizy J. L., Angelico M., Lesage G. Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha // Hepatology. 2002; 35 (5): 1041-1052. DOI: 10.1053/jhep.2002.32712.Alpini G., Baiocchi L., Glaser S., Ueno Y., Marzioni M., Francis H., Phinizy J. L., Angelico M., Lesage G. Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha // Hepatology. 2002; 35 (5): 1041-1052. DOI: 10.1053/jhep.2002.32712.Beuers U., Bilzer M., Chittattu A., Kullak-Ublick G. A., Keppler D., Paumgartner G., Dombrowski F. Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver // Hepatology. 2001; 33 (5): 1206-1216. DOI: 10.1053/jhep.2001.24034.Beuers U., Bilzer M., Chittattu A., Kullak-Ublick G. A., Keppler D., Paumgartner G., Dombrowski F. Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver // Hepatology. 2001; 33 (5): 1206-1216. DOI: 10.1053/jhep.2001.24034.Beuers U., Nathanson M. H., Isales C. M., Boyer J. L. Tauroursodeoxycholic acid stimulates hepatocellular exocytosis and mobilizes extracellular Ca++ mechanisms defective in cholestasis // J Clin Invest. 1993; 92 (6): 2984-2993. DOI: 10.1172/JCI116921.Beuers U., Nathanson M. H., Isales C. M., Boyer J. L. Tauroursodeoxycholic acid stimulates hepatocellular exocytosis and mobilizes extracellular Ca++ mechanisms defective in cholestasis // J Clin Invest. 1993; 92 (6): 2984-2993. DOI: 10.1172/JCI116921.Beuers U., Throckmorton D. C., Anderson M. S., Isales C. M., Thasler W., Kullak-Ublick G. A., Sauter G., Koebe H. G., Paumgartner G., Boyer J. L. Tauroursodeoxycholic acid activates protein kinase C in isolated rat hepatocytes // Gastroenterology. 1996; 110: 1553-1563. DOI: 10.1053/gast.1996.v110.pm8613063.Beuers U., Throckmorton D. C., Anderson M. S., Isales C. M., Thasler W., Kullak-Ublick G. A., Sauter G., Koebe H. G., Paumgartner G., Boyer J. L. Tauroursodeoxycholic acid activates protein kinase C in isolated rat hepatocytes // Gastroenterology. 1996; 110: 1553-1563. DOI: 10.1053/gast.1996.v110.pm8613063.Kitani K., Ohta M., Kanai S. Tauroursodeoxycholate prevents biliary protein excretion induced by other bile salts in the rat // Am J Physiol. 1985; 248 (4 Pt 1): G407-417. DOI: 10.1152/ajpgi.1985.248.4.G407.Kitani K., Ohta M., Kanai S. Tauroursodeoxycholate prevents biliary protein excretion induced by other bile salts in the rat // Am J Physiol. 1985; 248 (4 Pt 1): G407-417. DOI: 10.1152/ajpgi.1985.248.4.G407.Jazrawi R. P., de Caestecker J. S., Goggin P. M., Britten A. J., Joseph A. E., Maxwell J. D., Northfield T. C. Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid // Gastroenterology. 1994; 106 (1): 134-142. DOI: 10.1016/s0016-5085 (94)94899-2.Jazrawi R. P., de Caestecker J. S., Goggin P. M., Britten A. J., Joseph A. E., Maxwell J. D., Northfield T. C. Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid // Gastroenterology. 1994; 106 (1): 134-142. DOI: 10.1016/s0016-5085 (94)94899-2.Beuers U., Spengler U., Kruis W., Aydemir U., Wiebecke B., Heldwein W., Weinzierl M., Pape G. R., Sauerbruch T., Paumgartner G. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial // Hepatology. 1992; 16 (3): 707-714. DOI: 10.1002/hep.1840160315.Beuers U., Spengler U., Kruis W., Aydemir U., Wiebecke B., Heldwein W., Weinzierl M., Pape G. R., Sauerbruch T., Paumgartner G. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial // Hepatology. 1992; 16 (3): 707-714. DOI: 10.1002/hep.1840160315.Lindor K. D., Dickson E. R., Baldus W. P., Jorgensen R. A., Ludwig J., Murtaugh P. A., Harrison J. M., Wiesner R. H., Anderson M. L., Lange S. M., et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis // Gastroenterology. 1994; 106 (5): 1284-90. DOI: 10.1016/0016-5085(94)90021-3.Lindor K. D., Dickson E. R., Baldus W. P., Jorgensen R. A., Ludwig J., Murtaugh P. A., Harrison J. M., Wiesner R. H., Anderson M. L., Lange S. M., et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis // Gastroenterology. 1994; 106 (5): 1284-90. DOI: 10.1016/0016-5085(94)90021-3.Lindor K. D. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group // N Engl J Med. 1997; 336 (10): 691-695. DOI: 10.1056/NEJM199703063361003.Lindor K. D. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group // N Engl J Med. 1997; 336 (10): 691-695. DOI: 10.1056/NEJM199703063361003.Poupon R. E., Chretien Y., Poupon R., Paumgartner G. Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy // Hepatology. 1993; 17 (4): 599-604. DOI: 10.1002/hep.1840170412.Poupon R. E., Chretien Y., Poupon R., Paumgartner G. Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy // Hepatology. 1993; 17 (4): 599-604. DOI: 10.1002/hep.1840170412.Fickert P., Zollner G., Fuchsbichler A., Stumptner C., Pojer C., Zenz R., Lammert F., Stieger B., Meier P. J., Zatloukal K., Denk H., Trauner M. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver // Gastroenterology. 2001; 121 (1): 170-183. DOI: 10.1053/gast.2001.25542.Fickert P., Zollner G., Fuchsbichler A., Stumptner C., Pojer C., Zenz R., Lammert F., Stieger B., Meier P. J., Zatloukal K., Denk H., Trauner M. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver // Gastroenterology. 2001; 121 (1): 170-183. DOI: 10.1053/gast.2001.25542.Kurz A. K., Graf D., Schmitt M., Vom Dahl S., H?ussinger D. Tauroursodesoxycholate-induced choleresis involves p38 (MAPK) activation and translocation of the bile salt export pump in rats // Gastroenterology. 2001; 121 (2): 407-419. DOI: 10.1053/gast.2001.26262.Kurz A. K., Graf D., Schmitt M., Vom Dahl S., H?ussinger D. Tauroursodesoxycholate-induced choleresis involves p38 (MAPK) activation and translocation of the bile salt export pump in rats // Gastroenterology. 2001; 121 (2): 407-419. DOI: 10.1053/gast.2001.26262.H?ussinger D., Saha N., Hallbrucker C., Lang F., Gerok W. Involvement of microtubules in the swelling-induced stimulation of transcellular taurocholate transport in perfused rat liver // Biochem J. 1993; 291 (Pt 2): 355-360. DOI: 10.1042/bj2910355.H?ussinger D., Saha N., Hallbrucker C., Lang F., Gerok W. Involvement of microtubules in the swelling-induced stimulation of transcellular taurocholate transport in perfused rat liver // Biochem J. 1993; 291 (Pt 2): 355-360. DOI: 10.1042/bj2910355.Schliess F., Kurz A. K., vom Dahl S., H?ussinger D. Mitogen-activated protein kinases mediate the stimulation of bile acid secretion by tauroursodeoxycholate in rat liver // Gastroenterology. 1997; 113 (4): 1306-1314. DOI: 10.1053/gast.1997.v113.pm9322526.Schliess F., Kurz A. K., vom Dahl S., H?ussinger D. Mitogen-activated protein kinases mediate the stimulation of bile acid secretion by tauroursodeoxycholate in rat liver // Gastroenterology. 1997; 113 (4): 1306-1314. DOI: 10.1053/gast.1997.v113.pm9322526.Bouscarel B., Fromm H., Nussbaum R. Ursodeoxycholate mobilizes intracellular Ca2+ and activates phosphorylase a in isolated hepatocytes // Am J Physiol. 1993; 264 (2 Pt 1): G243-251. DOI: 10.1152/ajpgi.1993.264.2.G243.Bouscarel B., Fromm H., Nussbaum R. Ursodeoxycholate mobilizes intracellular Ca2+ and activates phosphorylase a in isolated hepatocytes // Am J Physiol. 1993; 264 (2 Pt 1): G243-251. DOI: 10.1152/ajpgi.1993.264.2.G243.Stravitz R. T., Rao Y. P., Vlahcevic Z. R., Gurley E. C., Jarvis W. D., Hylemon P. B. Hepatocellular protein kinase C activation by bile acids: implications for regulation of cholesterol 7 alpha-hydroxylase // Am J Physiol. 1996; 271 (2 Pt 1): G293-303. DOI: 10.1152/ajpgi.1996.271.2.G293.Stravitz R. T., Rao Y. P., Vlahcevic Z. R., Gurley E. C., Jarvis W. D., Hylemon P. B. Hepatocellular protein kinase C activation by bile acids: implications for regulation of cholesterol 7 alpha-hydroxylase // Am J Physiol. 1996; 271 (2 Pt 1): G293-303. DOI: 10.1152/ajpgi.1996.271.2.G293.Noe J., Hagenbuch B., Meier P. J., St-Pierre M. V. Characterization of the mouse bile salt export pump overexpressed in the baculovirus system // Hepatology. 2001; 33 (5): 1223-1231. DOI: 10.1053/jhep.2001.24171.Noe J., Hagenbuch B., Meier P. J., St-Pierre M. V. Characterization of the mouse bile salt export pump overexpressed in the baculovirus system // Hepatology. 2001; 33 (5): 1223-1231. DOI: 10.1053/jhep.2001.24171.Noe ? J. A., Meier P. J., St-Pierre M. V. Functional characterization of the phosphorylation of the bile salt export pump by protein kinase C [abstract] // Hepatology. 2001; 34 (Part 2): 255A.Noe ? J. A., Meier P. J., St-Pierre M. V. Functional characterization of the phosphorylation of the bile salt export pump by protein kinase C [abstract] // Hepatology. 2001; 34 (Part 2): 255A.Beuers U., Probst I, Soroka C., Boyer J. L., Kullak-Ublick G. A., Paumgartner G. Modulation of protein kinase C by taurolithocholic acid in isolated rat hepatocytes // Hepatology. 1999; 29 (2): 477-482. DOI: 10.1002/hep.510290227.Beuers U., Probst I, Soroka C., Boyer J. L., Kullak-Ublick G. A., Paumgartner G. Modulation of protein kinase C by taurolithocholic acid in isolated rat hepatocytes // Hepatology. 1999; 29 (2): 477-482. DOI: 10.1002/hep.510290227.Beuers U., Nathanson M. H., Boyer J. L. Effects of tauroursodeoxycholic acid on cytosolic Ca2+ signals in isolated rat hepatocytes // Gastroenterology. 1993; 104 (2): 604-612. DOI: 10.1016/0016-5085(93)90433-d.Beuers U., Nathanson M. H., Boyer J. L. Effects of tauroursodeoxycholic acid on cytosolic Ca2+ signals in isolated rat hepatocytes // Gastroenterology. 1993; 104 (2): 604-612. DOI: 10.1016/0016-5085(93)90433-d.Nathanson M. H., Burgstahler A. D., Masyuk A., Larusso N. F. Stimulation of ATP secretion in the liver by therapeutic bile acids // Biochem J. 2001; 358 (Pt 1): 1-5. DOI: 10.1042/0264-6021: 3580001.Nathanson M. H., Burgstahler A. D., Masyuk A., Larusso N. F. Stimulation of ATP secretion in the liver by therapeutic bile acids // Biochem J. 2001; 358 (Pt 1): 1-5. DOI: 10.1042/0264-6021: 3580001.Medina J. F., Martinez A., Vazquez J. J., Prieto J. Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis // Hepatology. 1997; 25 (1): 12-17. DOI: 10.1002/hep.510250104.Medina J. F., Martinez A., Vazquez J. J., Prieto J. Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis // Hepatology. 1997; 25 (1): 12-17. DOI: 10.1002/hep.510250104.Prieto J., Garcia N., Marti-Climent J. M., Penuelas I., Richter J. A., Medina J. F. Assessment of biliary bicarbonate secretion in humans by positron emission tomography // Gastroenterology. 1999; 117 (1): 167-172. DOI: 10.1016/s0016-5085 (99)70564-0.Prieto J., Garcia N., Marti-Climent J. M., Penuelas I., Richter J. A., Medina J. F. Assessment of biliary bicarbonate secretion in humans by positron emission tomography // Gastroenterology. 1999; 117 (1): 167-172. DOI: 10.1016/s0016-5085 (99)70564-0.Lazaridis K. N., Gores G. J., Lindor K. D. Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders' // J Hepatol. 2001; 35 (1): 134-146. DOI: 10.1016/s0168-8278 (01)00092-7.Lazaridis K. N., Gores G. J., Lindor K. D. Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders' // J Hepatol. 2001; 35 (1): 134-146. DOI: 10.1016/s0168-8278 (01)00092-7.Faubion W. A., Guicciardi M. E., Miyoshi H., Bronk S. F., Roberts P. J., Svingen P. A., Kaufmann S. H., Gores G. J. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas // J Clin Invest. 1999; 103 (1): 137-145. DOI: 10.1172/JCI4765.Faubion W. A., Guicciardi M. E., Miyoshi H., Bronk S. F., Roberts P. J., Svingen P. A., Kaufmann S. H., Gores G. J. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas // J Clin Invest. 1999; 103 (1): 137-145. DOI: 10.1172/JCI4765.Benz C., Angerm?ller S., T?x U., Kl?ters-Plachky P., Riedel H. D., Sauer P., Stremmel W., Stiehl A. Effect of tauroursodeoxycholic acid on bile-acid-induced apoptosis and cytolysis in rat hepatocytes // J Hepatol. 1998; 28 (1): 99-106. DOI: 10.1016/s0168-8278 (98)80208-0.Benz C., Angerm?ller S., T?x U., Kl?ters-Plachky P., Riedel H. D., Sauer P., Stremmel W., Stiehl A. Effect of tauroursodeoxycholic acid on bile-acid-induced apoptosis and cytolysis in rat hepatocytes // J Hepatol. 1998; 28 (1): 99-106. DOI: 10.1016/s0168-8278 (98)80208-0.Rodrigues C. M., Fan G., Wong P. Y., Kren B. T., Steer C. J. Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production // Mol Med. 1998; 4 (3): 165-178. PMCID: PMC2230355.Rodrigues C. M., Fan G., Wong P. Y., Kren B. T., Steer C. J. Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production // Mol Med. 1998; 4 (3): 165-178. PMCID: PMC2230355.Qiao L., Yacoub A., Studer E., Gupta S., Pei X. Y., Grant S., Hylemon P. B., Dent P. Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes // Hepatology. 2002; 35 (4): 779-789. DOI: 10.1053/jhep.2002.32533.Qiao L., Yacoub A., Studer E., Gupta S., Pei X. Y., Grant S., Hylemon P. B., Dent P. Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes // Hepatology. 2002; 35 (4): 779-789. DOI: 10.1053/jhep.2002.32533.Calmus Y., Gane P., Rouger P., Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid // Hepatology. 1990; 11 (1): 12-15. DOI: 10.1002/hep.1840110104.Calmus Y., Gane P., Rouger P., Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid // Hepatology. 1990; 11 (1): 12-15. DOI: 10.1002/hep.1840110104.Bergamini A., Dini L., Baiocchi L., Cappannoli L., Falasca L., Bolacchi F., Capozzi M., Faggioli E., Nistri A., Salanitro A., Ventura L., Rocchi G., Angelico M. Bile acids with differing hydrophilic-hydrophobic properties do not influence cytokine production by human monocytes and murine Kupffer cells // Hepatology. 1997; 25 (4): 927-933. DOI: 10.1002/hep.510250423.Bergamini A., Dini L., Baiocchi L., Cappannoli L., Falasca L., Bolacchi F., Capozzi M., Faggioli E., Nistri A., Salanitro A., Ventura L., Rocchi G., Angelico M. Bile acids with differing hydrophilic-hydrophobic properties do not influence cytokine production by human monocytes and murine Kupffer cells // Hepatology. 1997; 25 (4): 927-933. DOI: 10.1002/hep.510250423.Lindor K. D., Dickson E. R., Baldus W. P., Jorgensen R. A., Ludwig J., Murtaugh P. A., Harrison J. M., Wiesner R. H., Anderson M. L., Lange S M., et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis // Gastroenterology. 1994; 106 (5): 1284-1290. DOI: 10.1016/0016-5085 (94)90021-3.Lindor K. D., Dickson E. R., Baldus W. P., Jorgensen R. A., Ludwig J., Murtaugh P. A., Harrison J. M., Wiesner R. H., Anderson M. L., Lange S M., et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis // Gastroenterology. 1994; 106 (5): 1284-1290. DOI: 10.1016/0016-5085 (94)90021-3.The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis // Hepatology. 1994; 19 (5): 1149-1156. PMID: 8175136.The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis // Hepatology. 1994; 19 (5): 1149-1156. PMID: 8175136.Corpechot C., Carrat F., Bonnand A. M., Poupon R. E., Poupon R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis // Hepatology. 2000; 32 (6): 1196-1199. DOI: 10.1053/jhep.2000.20240.Corpechot C., Carrat F., Bonnand A. M., Poupon R. E., Poupon R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis // Hepatology. 2000; 32 (6): 1196-1199. DOI: 10.1053/jhep.2000.20240.Poupon R. E., Lindor K. D., Cauch-Dudek K., Dickson E. R., Poupon R., Heathcote E. J. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis // Gastroenterology. 1997; 113 (3): 884-890. DOI: 10.1016/s0016-5085 (97)70183-5.Poupon R. E., Lindor K. D., Cauch-Dudek K., Dickson E. R., Poupon R., Heathcote E. J. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis // Gastroenterology. 1997; 113 (3): 884-890. DOI: 10.1016/s0016-5085 (97)70183-5.Goulis J., Leandro G., Burroughs A. K. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis // Lancet. 1999; 354 (9184): 1053-1060. DOI: 10.1016/S0140-6736(98)11293-X.Goulis J., Leandro G., Burroughs A. K. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis // Lancet. 1999; 354 (9184): 1053-1060. DOI: 10.1016/S0140-6736(98)11293-X.Eriksson L. S., Olsson R., Glauman H., Prytz H., Befrits R., Ryd?n B. O., Einarsson K., Lindgren S., Wallerstedt S., Wed?n M. Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study // Scand J Gastroenterol. 1997; 32 (2): 179-186. DOI: 10.3109/00365529709000190.Eriksson L. S., Olsson R., Glauman H., Prytz H., Befrits R., Ryd?n B. O., Einarsson K., Lindgren S., Wallerstedt S., Wed?n M. Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study // Scand J Gastroenterol. 1997; 32 (2): 179-186. DOI: 10.3109/00365529709000190.Mitchell S. A., Bansi D. S., Hunt N., Von Bergmann K., Fleming K. A., Chapman R. W. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis // Gastroenterology. 2001; 121 (4): 900-907. DOI: 10.1053/gast.2001.27965.Mitchell S. A., Bansi D. S., Hunt N., Von Bergmann K., Fleming K. A., Chapman R. W. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis // Gastroenterology. 2001; 121 (4): 900-907. DOI: 10.1053/gast.2001.27965.Stiehl A., Rudolph G., Kloters-Plachky P., Sauer P., Walker S. Development of dominant bile duct stenoses in patients with primary sclerosing cholan- gitis treated with ursodeoxycholic acid: outcome after endoscopic treat- ment // J Hepatol. 2002; 36: 151-156.Stiehl A., Rudolph G., Kloters-Plachky P., Sauer P., Walker S. Development of dominant bile duct stenoses in patients with primary sclerosing cholan- gitis treated with ursodeoxycholic acid: outcome after endoscopic treat- ment // J Hepatol. 2002; 36: 151-156.Westbrook R. H., Dusheiko G., Williamson C. Pregnancy and liver disease // J Hepatol. 2016; 64 (4): 933-945. DOI: 10.1016/j.jhep.2015.11.030.Westbrook R. H., Dusheiko G., Williamson C. Pregnancy and liver disease // J Hepatol. 2016; 64 (4): 933-945. DOI: 10.1016/j.jhep.2015.11.030.Ovadia C., Seed P. T., Sklavounos A., Geenes V., Di Ilio C., Chambers J., et al. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses // Lancet. 2019; 393 (10174): 899-909. DOI: 10.1016/S0140-6736 (18)31877-4.Ovadia C., Seed P. T., Sklavounos A., Geenes V., Di Ilio C., Chambers J., et al. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses // Lancet. 2019; 393 (10174): 899-909. DOI: 10.1016/S0140-6736 (18)31877-4.Williamson C., Hems L. M., Goulis D. G., Walker I., Chambers J., Donaldson O., et al. Clinical outcome in a series of cases of obstetric cholestasis identified via a patient support group // BJOG. 2004; 111 (7): 676-681. DOI: 10.1111/j.1471-0528.2004.00167.x.Williamson C., Hems L. M., Goulis D. G., Walker I., Chambers J., Donaldson O., et al. Clinical outcome in a series of cases of obstetric cholestasis identified via a patient support group // BJOG. 2004; 111 (7): 676-681. DOI: 10.1111/j.1471-0528.2004.00167.x.Vallejo M., Briz O., Serrano M. A., Monte M. J., Marin J. J. Potential role of trans-inhibition of the bile salt export pump by progesterone metabolites in the etiopathogenesis of intrahepatic cholestasis of pregnancy // J Hepatol. 2006; 44 (6): 1150-1157. DOI: 10.1016/j.jhep.2005.09.017.Vallejo M., Briz O., Serrano M. A., Monte M. J., Marin J. J. Potential role of trans-inhibition of the bile salt export pump by progesterone metabolites in the etiopathogenesis of intrahepatic cholestasis of pregnancy // J Hepatol. 2006; 44 (6): 1150-1157. DOI: 10.1016/j.jhep.2005.09.017.Geenes V., Chambers J., Khurana R., Shemer E. W., Sia W., Mandair D., et al. Rifampicin in the treatment of severe intrahepatic cholestasis of pregnancy // Eur J Obstet Gynecol Reprod Biol. 2015; 189: 59-63. DOI: 10.1016/j.ejogrb.2015.03.020.Geenes V., Chambers J., Khurana R., Shemer E. W., Sia W., Mandair D., et al. Rifampicin in the treatment of severe intrahepatic cholestasis of pregnancy // Eur J Obstet Gynecol Reprod Biol. 2015; 189: 59-63. DOI: 10.1016/j.ejogrb.2015.03.020.Kong X., Kong Y., Zhang F., Wang T., Yan J. Evaluating the effectiveness and safety of ursodeoxycholic acid in treatment of intrahepatic cholestasis of pregnancy: A meta-analysis (a prisma-compliant study) // Medicine (Baltimore). 2016; 95 (40): e4949. DOI: 10.1097/MD.0000000000004949.Kong X., Kong Y., Zhang F., Wang T., Yan J. Evaluating the effectiveness and safety of ursodeoxycholic acid in treatment of intrahepatic cholestasis of pregnancy: A meta-analysis (a prisma-compliant study) // Medicine (Baltimore). 2016; 95 (40): e4949. DOI: 10.1097/MD.0000000000004949.Davit-Spraul A., Gonzales E., Baussan C., Jacquemin E. The spectrum of liver diseases related to ABCB4 gene mutations: pathophysiology and clinical aspect // Semin Liver Dis. 2010; 30 (2): 134-146. DOI: 10.1055/s-0030-1253223.Davit-Spraul A., Gonzales E., Baussan C., Jacquemin E. The spectrum of liver diseases related to ABCB4 gene mutations: pathophysiology and clinical aspect // Semin Liver Dis. 2010; 30 (2): 134-146. DOI: 10.1055/s-0030-1253223.Colombo C., Battezzati P. M., Podda M., Bettinardi N., Giunta A. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis // Hepatology. 1996; 23 (6): 1484-1490. DOI: 10.1002/hep.510230627.Colombo C., Battezzati P. M., Podda M., Bettinardi N., Giunta A. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis // Hepatology. 1996; 23 (6): 1484-1490. DOI: 10.1002/hep.510230627.Lindblad A., Glaumann H., Strandvik B. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease // Hepatology. 1998; 27 (1): 166-174. DOI: 10.1002/hep.510270126.Lindblad A., Glaumann H., Strandvik B. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease // Hepatology. 1998; 27 (1): 166-174. DOI: 10.1002/hep.510270126.Van de Meeberg P. C., Houwen R. H., Sinaasappel M., Heijerman H. G., Bijleveld C. M., Vanberge-Henegouwen G. P. Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease. Results of a randomized study with 1-year follow-up // Scand J Gastroenterol. 1997; 32 (4): 369-373. DOI: 10.3109/00365529709007686.Van de Meeberg P. C., Houwen R. H., Sinaasappel M., Heijerman H. G., Bijleveld C. M., Vanberge-Henegouwen G. P. Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease. Results of a randomized study with 1-year follow-up // Scand J Gastroenterol. 1997; 32 (4): 369-373. DOI: 10.3109/00365529709007686.Colombo C., Vajro P., Degiorgio D., Coviello D. A., Costantino L., Tornillo L., et al. Clinical features and genotype-phenotype correlations in children with progressive familial intrahepatic cholestasis type 3 related to ABCB4 mutations // J Pediatr Gastroenterol Nutr. 2011; 52 (1): 73-83. DOI: 10.1097/MPG.0b013e3181f50363.Colombo C., Vajro P., Degiorgio D., Coviello D. A., Costantino L., Tornillo L., et al. Clinical features and genotype-phenotype correlations in children with progressive familial intrahepatic cholestasis type 3 related to ABCB4 mutations // J Pediatr Gastroenterol Nutr. 2011; 52 (1): 73-83. DOI: 10.1097/MPG.0b013e3181f50363.Degiorgio D., Crosignani A., Colombo C., Bordo D., Zuin M., Vassallo E., et al. ABCB4 mutations in adult patients with cholestatic liver disease: impact and phenotypic expression // J Gastroenterol. 2016; 51 (3): 271-280. DOI: 10.1007/s00535-015-1110-z.Degiorgio D., Crosignani A., Colombo C., Bordo D., Zuin M., Vassallo E., et al. ABCB4 mutations in adult patients with cholestatic liver disease: impact and phenotypic expression // J Gastroenterol. 2016; 51 (3): 271-280. DOI: 10.1007/s00535-015-1110-z.Gordo-Gilart R., Hierro L., Andueza S., Mu?oz-Bartolo G., L?pez C., D?az C., et al. Heterozygous ABCB4 mutations in children with cholestatic liver disease // Liver Int. 2016; 36 (2): 258-267. DOI: 10.1111/liv.12910.Gordo-Gilart R., Hierro L., Andueza S., Mu?oz-Bartolo G., L?pez C., D?az C., et al. Heterozygous ABCB4 mutations in children with cholestatic liver disease // Liver Int. 2016; 36 (2): 258-267. DOI: 10.1111/liv.12910.Hori T., Nguyen J. H., Uemoto S. Progressive familial intrahepatic cholestasis // Hepatobiliary Pancreat Dis Int. 2010; 9 (6): 570-578. PMID: 21134824.Hori T., Nguyen J. H., Uemoto S. Progressive familial intrahepatic cholestasis // Hepatobiliary Pancreat Dis Int. 2010; 9 (6): 570-578. PMID: 21134824.Stapelbroek J. M., van Erpecum K. J., Klomp L. W., Houwen R. H. Liver disease associated with canalicular transport defects: current and future therapies // J Hepatol. 2010; 52 (2): 258-271. DOI: 10.1016/j.jhep.2009.11.012.Stapelbroek J. M., van Erpecum K. J., Klomp L. W., Houwen R. H. Liver disease associated with canalicular transport defects: current and future therapies // J Hepatol. 2010; 52 (2): 258-271. DOI: 10.1016/j.jhep.2009.11.012.Morotti R. A., Suchy F. J., Magid M. S. Progressive familial intrahepatic cholestasis (PFIC) type 1, 2, and 3: a review of the liver pathology findings // Semin Liver Dis. 2011; 31 (1): 3-10. DOI: 10.1055/s-0031-1272831.Morotti R. A., Suchy F. J., Magid M. S. Progressive familial intrahepatic cholestasis (PFIC) type 1, 2, and 3: a review of the liver pathology findings // Semin Liver Dis. 2011; 31 (1): 3-10. DOI: 10.1055/s-0031-1272831.Knisely A. S., Strautnieks S. S., Meier Y., Stieger B., Byrne J. A., Portmann B. C., et al. Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency // Hepatology. 2006; 44 (2): 478-486. DOI: 10.1002/hep.21287.Knisely A. S., Strautnieks S. S., Meier Y., Stieger B., Byrne J. A., Portmann B. C., et al. Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency // Hepatology. 2006; 44 (2): 478-486. DOI: 10.1002/hep.21287.Gomez-Ospina N., Potter C. J., Xiao R., Manickam K., Kim M. S., Kim K. H., et al. Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis // Nat Commun. 2016; 7: 10713. DOI: 10.1038/ncomms10713.Gomez-Ospina N., Potter C. J., Xiao R., Manickam K., Kim M. S., Kim K. H., et al. Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis // Nat Commun. 2016; 7: 10713. DOI: 10.1038/ncomms10713.Herbst S. M., Schirmer S., Posovszky C., Jochum F., R?dl T., Schroeder J. A., et al. Taking the next step forward - Diagnosing inherited infantile cholestatic disorders with next generation sequencing // Mol Cell Probes. 2015; 29 (5): 291-298. DOI: 10.1016/j.mcp.2015.03.001.Herbst S. M., Schirmer S., Posovszky C., Jochum F., R?dl T., Schroeder J. A., et al. Taking the next step forward - Diagnosing inherited infantile cholestatic disorders with next generation sequencing // Mol Cell Probes. 2015; 29 (5): 291-298. DOI: 10.1016/j.mcp.2015.03.001.Sambrotta M., Strautnieks S., Papouli E., Rushton P., Clark B. E., Parry D. A., et al. Mutations in TJP2 cause progressive cholestatic liver disease // Nat Genet. 2014; 46 (4): 326-8. DOI: 10.1038/ng.2918.Sambrotta M., Strautnieks S., Papouli E., Rushton P., Clark B. E., Parry D. A., et al. Mutations in TJP2 cause progressive cholestatic liver disease // Nat Genet. 2014; 46 (4): 326-8. DOI: 10.1038/ng.2918.Gonzales E., Taylor S. A., Davit-Spraul A., Th?baut A., Thomassin N., Guettier C., et al. MYO5B mutations cause cholestasis with normal serum gamma-glutamyl transferase activity in children without microvillous inclusion disease // Hepatology. 2017; 65 (1): 164-173. DOI: 10.1002/hep.28779.Gonzales E., Taylor S. A., Davit-Spraul A., Th?baut A., Thomassin N., Guettier C., et al. MYO5B mutations cause cholestasis with normal serum gamma-glutamyl transferase activity in children without microvillous inclusion disease // Hepatology. 2017; 65 (1): 164-173. DOI: 10.1002/hep.28779.Qiu Y. L., Gong J. Y., Feng J. Y., Wang R. X, Han J., Liu T., et al. Defects in myosin VB are associated with a spectrum of previously undiagnosed low ?-glutamyltransferase cholestasis // Hepatology. 2017; 65 (5): 1655-1669. DOI: 10.1002/hep.29020.Qiu Y. L., Gong J. Y., Feng J. Y., Wang R. X, Han J., Liu T., et al. Defects in myosin VB are associated with a spectrum of previously undiagnosed low ?-glutamyltransferase cholestasis // Hepatology. 2017; 65 (5): 1655-1669. DOI: 10.1002/hep.29020.Jacquemin E., Hermans D., Myara A., Habes D., Debray D., Hadchouel M., et al. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis // Hepatology. 1997; 25 (3): 519-523. DOI: 10.1002/hep.510250303.Jacquemin E., Hermans D., Myara A., Habes D., Debray D., Hadchouel M., et al. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis // Hepatology. 1997; 25 (3): 519-523. DOI: 10.1002/hep.510250303.Folvik G., Hilde O., Helge G. O. Benign recurrent intrahepatic cholestasis: review and long-term follow-up of five cases // Scand J Gastroenterol. 2012; 47 (4): 482-488. DOI: 10.3109/00365521.2011.650191.Folvik G., Hilde O., Helge G. O. Benign recurrent intrahepatic cholestasis: review and long-term follow-up of five cases // Scand J Gastroenterol. 2012; 47 (4): 482-488. DOI: 10.3109/00365521.2011.650191.Srivastava A. Progressive familial intrahepatic cholestasis // J Clin Exp Hepatol. 2014; 4 (1): 25-36. DOI: 10.1016/j.jceh.2013.10.005.Srivastava A. Progressive familial intrahepatic cholestasis // J Clin Exp Hepatol. 2014; 4 (1): 25-36. DOI: 10.1016/j.jceh.2013.10.005.Stange J., Hassanein T. I., Mehta R., Mitzner S. R., Bartlett R. H. The molecular adsorbents recycling system as a liver support system based on albumin dialysis: a summary of preclinical investigations, prospective, randomized, controlled clinical trial, and clinical experience from 19 centers // Artif Organs. 2002; 26 (2): 103-110. PMID: 11879237.Stange J., Hassanein T. I., Mehta R., Mitzner S. R., Bartlett R. H. The molecular adsorbents recycling system as a liver support system based on albumin dialysis: a summary of preclinical investigations, prospective, randomized, controlled clinical trial, and clinical experience from 19 centers // Artif Organs. 2002; 26 (2): 103-110. PMID: 11879237.Hollands C. M., Rivera-Pedrogo F. J., Gonzalez-Vallina R., Loret-de-Mola O., Nahmad M., Burnweit C. A. Ileal exclusion for Byler's disease: an alternative surgical approach with promising early results for pruritus // J Pediatr Surg. 1998; 33 (2): 220-224. PMID: 9498390.Hollands C. M., Rivera-Pedrogo F. J., Gonzalez-Vallina R., Loret-de-Mola O., Nahmad M., Burnweit C. A. Ileal exclusion for Byler's disease: an alternative surgical approach with promising early results for pruritus // J Pediatr Surg. 1998; 33 (2): 220-224. PMID: 9498390.Essell J. H., Schroeder M. T., Harman G. S., Halvorson R., Lew V., Callander N., Snyder M., Lewis S. K., Allerton J. P., Thompson J. M. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial // Ann Intern Med. 1998; 128 (12 Pt 1): 975-981. DOI: 10.7326/0003-4819-128-12_part_1-199806150-00002.Essell J. H., Schroeder M. T., Harman G. S., Halvorson R., Lew V., Callander N., Snyder M., Lewis S. K., Allerton J. P., Thompson J. M. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial // Ann Intern Med. 1998; 128 (12 Pt 1): 975-981. DOI: 10.7326/0003-4819-128-12_part_1-199806150-00002.Pauli-Magnus C., Meier P. J., Stieger B. Genetic determinants of drug-induced cholestasis and intrahepatic cholestasis of pregnancy // Semin Liver Dis. 2010; 30 (2): 147-159. DOI: 10.1055/s-0030-1253224.Pauli-Magnus C., Meier P. J., Stieger B. Genetic determinants of drug-induced cholestasis and intrahepatic cholestasis of pregnancy // Semin Liver Dis. 2010; 30 (2): 147-159. DOI: 10.1055/s-0030-1253224.Padda M. S., Sanchez M., Akhtar A. J., Boyer J. L. Drug-induced cholestasis // Hepatology. 2011; 53 (4): 1377-1387. DOI: 10.1002/hep.24229.Padda M. S., Sanchez M., Akhtar A. J., Boyer J. L. Drug-induced cholestasis // Hepatology. 2011; 53 (4): 1377-1387. DOI: 10.1002/hep.24229.Nakanishi Y., Saxena R. Pathophysiology and Diseases of the Proximal Pathways of the Biliary System // Arch Pathol Lab Med. 2015; 139 (7): 858-866. DOI: 10.5858/arpa.2014-0229-RA.Nakanishi Y., Saxena R. Pathophysiology and Diseases of the Proximal Pathways of the Biliary System // Arch Pathol Lab Med. 2015; 139 (7): 858-866. DOI: 10.5858/arpa.2014-0229-RA.Bodin K., Bretillon L., Aden Y., Bertilsson L., Broom? U., Einarsson C., Diczfalusy U. Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4 // J Biol Chem. 2001; 276 (42): 38685-38789. DOI: 10.1074/jbc.M105127200.Bodin K., Bretillon L., Aden Y., Bertilsson L., Broom? U., Einarsson C., Diczfalusy U. Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4 // J Biol Chem. 2001; 276 (42): 38685-38789. DOI: 10.1074/jbc.M105127200.EASL clinical practice guidelines: management of cholestatic liver diseases // J Hepatol. 2009; 51 (2): 237-267. DOI: 10.1016/j.jhep.2009.04.009.EASL clinical practice guidelines: management of cholestatic liver diseases // J Hepatol. 2009; 51 (2): 237-267. DOI: 10.1016/j.jhep.2009.04.009.Tajiri K., Shimizu Y. Recent advances in the management of pruritus in chronic liver diseases // World J Gastroenterol. 2017, May 21; 23 (19): 3418-3426. DOI: 10.3748/wjg.v23.i19.3418.Tajiri K., Shimizu Y. Recent advances in the management of pruritus in chronic liver diseases // World J Gastroenterol. 2017, May 21; 23 (19): 3418-3426. DOI: 10.3748/wjg.v23.i19.3418.Jankowska I., Czubkowski P., Kalici?ski P., Ismail H., Kowalski A., Ry?ko J., Paw?owska J. Ileal exclusion in children with progressive familial intrahepatic cholestasis // J Pediatr Gastroenterol Nutr. 2014; 58 (1): 92-95. DOI: 10.1097/MPG.0b013e3182a9097c.Jankowska I., Czubkowski P., Kalici?ski P., Ismail H., Kowalski A., Ry?ko J., Paw?owska J. Ileal exclusion in children with progressive familial intrahepatic cholestasis // J Pediatr Gastroenterol Nutr. 2014; 58 (1): 92-95. DOI: 10.1097/MPG.0b013e3182a9097c.Gonzales E., Gerhardt M. F., Fabre M., Setchell K. D., Davit-Spraul A., Vincent I, Heubi J. E., Bernard O., Jacquemin E. Oral cholic acid for hereditary defects of primary bile acid synthesis: a safe and effective long-term therapy // Gastroenterology. 2009; 137 (4): 1310-1320. DOI: 10.1053/j.gastro.2009.07.043.Gonzales E., Gerhardt M. F., Fabre M., Setchell K. D., Davit-Spraul A., Vincent I, Heubi J. E., Bernard O., Jacquemin E. Oral cholic acid for hereditary defects of primary bile acid synthesis: a safe and effective long-term therapy // Gastroenterology. 2009; 137 (4): 1310-1320. DOI: 10.1053/j.gastro.2009.07.043.Beuers U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis // Nat Clin Pract Gastroenterol Hepatol. 2006; 3 (6): 318-328. DOI: 10.1038/ncpgasthep0521.Beuers U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis // Nat Clin Pract Gastroenterol Hepatol. 2006; 3 (6): 318-328. DOI: 10.1038/ncpgasthep0521.Poupon R. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action // Clin Res Hepatol Gastroenterol. 2012; 36 Suppl 1: S3-12. DOI: 10.1016/S2210-7401 (12)70015-3.Poupon R. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action // Clin Res Hepatol Gastroenterol. 2012; 36 Suppl 1: S3-12. DOI: 10.1016/S2210-7401 (12)70015-3.Волынец Г. В. Семейный внутрипеченочный холестаз у детей: проблемы и перспективы // Российский педиатрический журнал. 2019; 22: (6): 388-394. [Volynets G. V. Semeyny vnutripechenochny kholestaz u detey: problem i perspektivy [Familial intrahepatic cholestasis in children: problems and prospects] // Russian Pediatric Journal. 2019; 22: (6): 388-394. DOI: 10.18821/1560-9561-2019-22-6-388-394.]Волынец Г. В. Семейный внутрипеченочный холестаз у детей: проблемы и перспективы // Российский педиатрический журнал. 2019; 22: (6): 388-394. [Volynets G. V. Semeyny vnutripechenochny kholestaz u detey: problem i perspektivy [Familial intrahepatic cholestasis in children: problems and prospects] // Russian Pediatric Journal. 2019; 22: (6): 388-394. DOI: 10.18821/1560-9561-2019-22-6-388-394.]Davit-Spraul A., Fabre M., Branchereau S., Baussan C., Gonzales E., Stieger B., Bernard O., Jacquemin E. ATP8B1 and ABCB11 analysis in 62 children with normal gamma-glutamyl transferase progressive familial intrahepatic cholestasis (PFIC): phenotypic differences between PFIC1 and PFIC2 and natural history // Hepatology. 2010; 51 (5): 1645-1655. DOI: 10.1002/hep.23539.Davit-Spraul A., Fabre M., Branchereau S., Baussan C., Gonzales E., Stieger B., Bernard O., Jacquemin E. ATP8B1 and ABCB11 analysis in 62 children with normal gamma-glutamyl transferase progressive familial intrahepatic cholestasis (PFIC): phenotypic differences between PFIC1 and PFIC2 and natural history // Hepatology. 2010; 51 (5): 1645-1655. DOI: 10.1002/hep.23539.Jacquemin E., Hermans D., Myara A., Habes D., Debray D., Hadchouel M., Sokal E. M., Bernard O. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis // Hepatology. 1997; 25 (3): 519-523. DOI: 10.1002/hep.510250303.Jacquemin E., Hermans D., Myara A., Habes D., Debray D., Hadchouel M., Sokal E. M., Bernard O. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis // Hepatology. 1997; 25 (3): 519-523. DOI: 10.1002/hep.510250303.Willot S., Uhlen S., Michaud L., Briand G., Bonnevalle M., Sfeir R., Gottrand F. Effect of ursodeoxycholic acid on liver function in children after successful surgery for biliary atresia // Pediatrics. 2008; 122 (6): e1236-41. DOI: 10.1542/peds.2008-0986.Willot S., Uhlen S., Michaud L., Briand G., Bonnevalle M., Sfeir R., Gottrand F. Effect of ursodeoxycholic acid on liver function in children after successful surgery for biliary atresia // Pediatrics. 2008; 122 (6): e1236-41. DOI: 10.1542/peds.2008-0986.Fisher V. J., Sewell W. A., Holding S. Predictive value of anti-mitochondrial antibodies for development of cholestasis and primary billary cirrhosis // Gastroenterol. 2013; 144: 966.Fisher V. J., Sewell W. A., Holding S. Predictive value of anti-mitochondrial antibodies for development of cholestasis and primary billary cirrhosis // Gastroenterol. 2013; 144: 966.Rosmorduc O., Poupon R. Low phospholipid associated cholelithiasis: association with mutation in the MDR3/ABCB4 gene // Orphanet J Rare Dis. 2007; 11 (2): 29. DOI: 10.1186/1750-1172-2-29.Rosmorduc O., Poupon R. Low phospholipid associated cholelithiasis: association with mutation in the MDR3/ABCB4 gene // Orphanet J Rare Dis. 2007; 11 (2): 29. DOI: 10.1186/1750-1172-2-29.

The authors declare that there are no conflicts of interest present.